20^th European Gastroenterology and Therapeutics Congress

Inflammatory Bowel Disease (IBD): Insights and Advancements

Inflammatory Bowel Disease (IBD), comprising Crohn’s disease and ulcerative colitis, remains a complex and chronic inflammatory condition of the gastrointestinal tract. This session explores the latest scientific and clinical advancements in IBD pathogenesis, diagnosis, and treatment. New insights into immune dysregulation, genetic predisposition, and microbiome interactions are driving innovative therapeutic approaches. The emergence of biologics, JAK inhibitors, and gut-selective agents has revolutionized disease management by targeting specific immune pathways, leading to better mucosal healing and fewer relapses. Additionally, non-invasive biomarkers like fecal calprotectin and imaging modalities are enhancing early diagnosis and disease monitoring. Personalized treatment algorithms and therapeutic drug monitoring are improving long-term outcomes and reducing adverse effects. The session will also address pediatric IBD, lifestyle modification strategies, and emerging trends like stem cell therapy. With a multidisciplinary approach, these advancements offer renewed hope for improving quality of life in patients suffering from IBD.